What is the recommended method to convert a patient receiving 1200 mg daily extended‑release morphine (Kadian) to methadone for treatment of opioid use disorder?

Converting 1200 mg Daily Kadian to Methadone for Opioid Use Disorder

Critical Safety Warning

Do not use standard morphine-to-methadone conversion tables for doses ≥800 mg/day morphine equivalents—this approach carries significant overdose risk and requires mandatory cross-titration with specialist consultation. 1, 2

---

Why Standard Conversion Fails at This Dose

• At 1200 mg daily morphine, methadone becomes disproportionately more potent due to non-linear pharmacokinetics, making equianalgesic tables dangerously inaccurate. 3, 1
• The National Comprehensive Cancer Network explicitly states that doses ≥800 mg morphine require "higher dose-ratio conversion and cross-titration" rather than direct calculation. 3, 1
• Deaths have been reported during conversion from chronic high-dose opioids to methadone, even in highly tolerant patients. 2

---

Mandatory Pre-Conversion Steps

Cardiac Risk Assessment

• Obtain a baseline ECG before initiating methadone to assess QTc interval. 1, 2
• Screen for cardiac disease, electrolyte abnormalities (hypokalemia, hypomagnesemia), and concomitant QTc-prolonging medications (tricyclics, certain antiarrhythmics, diuretics). 1
• Methadone doses >100 mg/day require repeat ECG monitoring due to risk of torsades de pointes. 1

Drug Interaction Review

• Evaluate all medications for CYP3A4 and CYP2B6 interactions before starting methadone. 1
• CYP inhibitors (azole antifungals, macrolides, protease inhibitors) increase methadone levels and toxicity risk. 1
• CYP inducers (rifampin, phenytoin, carbamazepine) decrease methadone efficacy and may precipitate withdrawal. 1

Specialist Consultation

• Strong consideration for pain specialist or addiction medicine consultation is required for any patient on >800 mg morphine daily due to conversion complexity and mortality risk. 1
• Mandatory specialist involvement if QTc >450 ms, cardiac conduction disease, or complex polypharmacy exists. 1

---

The Cross-Titration Protocol

Day 1: Initiate Methadone While Maintaining Full Morphine Dose

Start methadone at 30 mg/day maximum, divided into 3–4 doses (e.g., 10 mg every 8 hours or 7.5 mg every 6 hours). 1, 2

• Continue the full 1200 mg daily Kadian dose unchanged on day 1. 1
• The FDA label specifies that initial methadone dosing should not exceed 30 mg on the first day, even in highly tolerant patients. 2
• This conservative start prevents overdose while allowing methadone tissue stores to accumulate over its 24–36 hour half-life. 1

Days 2–5: Observe Without Dose Changes

• Do not adjust either medication during the first 3–5 days. 1
• Methadone does not reach steady-state for 5–7 days after each dose change due to its long elimination half-life. 1
• Monitor for sedation, respiratory depression, and withdrawal symptoms during this observation period. 1

Days 6 Onward: Begin Morphine Taper

• After 3–5 days of stable methadone dosing, reduce Kadian by 25–50% every 3–5 days. 1
• Provide immediate-release morphine for breakthrough pain at 10–15% of the remaining daily morphine dose. 1
• Continue this stepwise morphine reduction until fully discontinued, typically over 2–4 weeks. 1

Methadone Titration After Morphine Discontinuation

• Once Kadian is fully stopped, methadone may be increased by 5–10 mg per dose every 5–7 days based on withdrawal symptoms and pain control. 1, 2
• Allow a minimum of 5–7 days between methadone dose adjustments to reach steady-state. 1
• Most patients stabilize on 80–120 mg/day methadone for maintenance treatment of opioid use disorder. 2

---

Mandatory Concurrent Management

Bowel Regimen

• Start senna plus docusate, 2 tablets every morning, on day 1 of methadone therapy. 1
• Increase laxative dose proportionally as methadone is titrated upward—opioid-induced constipation does not improve with tolerance. 1
• Ensure adequate hydration (≥2 liters daily if medically appropriate). 1

Cardiac Monitoring Schedule

• Repeat ECG when methadone dose exceeds 100 mg/day. 1
• Repeat ECG if any new QTc-prolonging medication is added during the conversion. 1

---

Critical Pitfalls to Avoid

Never Calculate a Direct Conversion Ratio

• Do not multiply 1200 mg morphine by any conversion factor to determine a starting methadone dose—this will result in overdose. 3, 1, 2
• Standard tables (e.g., 3:1,5:1,10:1 ratios) are only valid for morphine doses <300 mg/day. 3

Never Abruptly Stop the Morphine

• Discontinuing 1200 mg Kadian without cross-titration will precipitate severe withdrawal and high relapse risk. 1, 2
• The gradual taper allows methadone to assume analgesic and anti-withdrawal effects as morphine is reduced. 1

Never Increase Methadone Faster Than Every 5–7 Days

• Same-day or daily methadone dose increases cause cumulative toxicity—deaths have occurred from this practice. 1, 2
• The FDA label explicitly warns that "deaths have occurred in early treatment due to the cumulative effects of the first several days' dosing." 2

Never Assume Tolerance Eliminates Overdose Risk

• The FDA states: "A high degree of 'opioid tolerance' does not eliminate the possibility of methadone overdose, iatrogenic or otherwise." 2
• Methadone's unique pharmacology (NMDA antagonism, serotonin-norepinephrine reuptake inhibition) differs from pure mu-agonists like morphine, making cross-tolerance incomplete. 1

---

Monitoring During Conversion

Daily Assessment (First 2 Weeks)

• Evaluate for sedation, confusion, respiratory rate <10/minute, and pupil size. 1, 2
• Assess withdrawal symptoms using a validated scale (e.g., Clinical Opiate Withdrawal Scale). 2
• Document breakthrough morphine use to guide taper speed. 1

Weekly Assessment (Weeks 3–6)

• Monitor pain control and withdrawal symptoms. 1
• Adjust methadone dose by 5–10 mg per dose if indicated, waiting 5–7 days between changes. 1
• Reassess cardiac risk factors and medication interactions. 1

---

Context: Why This Patient Needs Methadone for OUD

• For opioid use disorder, methadone maintenance at 80–120 mg/day reduces illicit opioid use, overdose mortality, and infectious disease transmission. 2
• Methadone must be dispensed through a federally certified opioid treatment program (OTP) in accordance with 42 CFR Section 8.12 for OUD treatment. 2
• The cross-titration approach allows safe transition from prescribed high-dose morphine to supervised methadone maintenance without precipitating withdrawal or relapse. 1, 2